InflaRx to Present at Upcoming Scientific and Investor Conferences
September 09 2022 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, today announced its participation at several
conferences.
H.C. Wainwright
24th Annual Global Investment
Conference, New York, NY USA: Prof. Niels C. Riedemann,
Chief Executive Officer and Founder of InflaRx, will provide a
general corporate overview and update on Wednesday,
September 14th at 9:30 am EDT
(3:30 pm CEST). A link to the live stream of the
presentation and a replay following the live event will be provided
on the InflaRx website in the Investors – Events &
Presentations section.
10th
World Sepsis Day, Berlin, Germany: Prof. Riedemann
will participate in a podium discussion organized by the Global
Sepsis Alliance and the German Sepsis Foundation on
September 16th. In advance of the
event, a press conference was held on September 9th at the German
Federal Press Conference (“Bundespressekonferenz”) at which Prof.
Riedemann discussed “Innovative Therapeutics in Viral Sepsis.”
6th
Complement Drug Development Summit, Boston, MA
USA: Prof. Dr. Renfeng Guo, Chief Scientific Officer and
Co-founder of InflaRx, will give a presentation on
Wednesday, September 28th
entitled, “Treatment of Critically Ill COVID-19 Patients with
Vilobelimab, a First-in-Class Anti-C5a Antibody.“
35th
Annual Congress, European Society for Intensive Care
Medicine (ESICM), Paris, France: Prof. Dr. Alexander
Vlaar, principal investigator of the PANAMO Phase III trial, will
present a poster on October 24 entitled, “Vilobelimab Treatment in
Mechanically Ventilated Patients with COVID-19: A Randomized
Controlled Phase III Trial.”
About InflaRx N.V.InflaRx
(Nasdaq: IFRX) is a clinical-stage biopharmaceutical company
focused on applying its proprietary technology to discover and
develop first-in-class or best-in-class, potent and specific
inhibitors of C5a and C5aR. Complement C5a and its receptor C5aR
are powerful inflammatory mediators involved in the progression of
a wide variety of autoimmune and other inflammatory diseases.
InflaRx was founded in 2007, and the group has offices and
subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI,
USA. For further information, please visit www.inflarx.com.
Contacts:
InflaRx N.V.Email:
IR@inflarx.de
MC Services AGKatja Arnold,
Laurie Doyle, Andreas JungferEmail: inflarx@mc-services.euEurope:
+49 89-210 2280US: +1-339-832-0752
FORWARD-LOOKING
STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “believe,” “estimate,”
“predict,” “potential” or “continue” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and may include statements regarding InflaRx’s
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the Company’s ongoing
and planned pre-clinical development and clinical trials, including
the development of vilobelimab in several indications; the
Company’s interactions with regulators regarding the results of
clinical trials and potential regulatory approval pathways; the
Company’s submission of an application to the FDA in the third
quarter of 2022 for emergency use authorization for vilobelimab to
treat critically ill COVID-19 patients; the impact of the COVID-19
pandemic on the Company; the timing and its ability to commence and
conduct clinical trials; potential results from current or
potential future collaborations; its ability to make regulatory
filings, obtain positive guidance from regulators and obtain and
maintain regulatory approvals for its product candidates; its
intellectual property position; its ability to develop commercial
functions; expectations regarding clinical trial data; decisions
regarding the strategic direction of the Company; its results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies; the industry in which
the Company operates; the trends that may affect the industry or
the Company; and the risks, uncertainties and other factors
described under the heading “Risk Factors” in InflaRx’s periodic
filings with the Securities and Exchange Commission. These
statements speak only as of the date of this press release and
involve known and unknown risks, uncertainties and other important
factors that may cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and
other factors, you should not place undue reliance on these
forward-looking statements, and InflaRx assumes no obligation to
update these forward-looking statements, even if new information
becomes available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024